DERM
NASDAQJourney Medical Corporation
Price$6.33+0.12 (+1.85%)
01:45 PM07:45 PM
News · 26 weeks20-91%
2025-12-142026-06-07
Mix1690d
- SEC Filings6(38%)
- Earnings4(25%)
- Other3(19%)
- Insider3(19%)
Latest news
25 items- PRJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceSCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET. To register for the conference, visit the A.G.P. Registration Link. About Journey Medical Corpora
- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsTotal revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corp
- PRJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the
- SECSEC Form DEFA14A filed by Journey Medical CorporationDEFA14A - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form DEF 14A filed by Journey Medical CorporationDEF 14A - Journey Medical Corp (0001867066) (Filer)
- INSIDERChief Operating Officer Alloush Ramsey was granted 46,863 shares, increasing direct ownership by 8% to 598,543 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERCFO Benesch Joseph was granted 28,907 shares, increasing direct ownership by 12% to 261,371 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERPresident & CEO Maraoui Claude was granted 49,277 shares, increasing direct ownership by 2% to 2,435,990 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- SECJourney Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi™SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Journey Medical CorporationSCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsTotal revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t
- PRJourney Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul
- SECSEC Form 424B3 filed by Journey Medical Corporation424B3 - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form 424B3 filed by Journey Medical Corporation424B3 - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form EFFECT filed by Journey Medical CorporationEFFECT - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form S-3 filed by Journey Medical CorporationS-3 - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyClinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administrat
- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsThird quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar
- PRJourney Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the
DERM FAQ
7 questionsWhat does Journey Medical Corporation do?
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm...Where does DERM stock trade?
Journey Medical Corporation (DERM) is listed on NASDAQ.What sector and industry is DERM in?
Journey Medical Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Journey Medical Corporation go public?
Journey Medical Corporation (DERM) completed its IPO in 2021.What are analysts saying about DERM?
Journey Medical Corporation has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1300.00 price target on 2025-08-25. Recent price targets range from $900.00 to $1500.00.What companies are similar to DERM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DERM side-by-side with any of them on Quantisnow.How can I track DERM on Quantisnow?
Quantisnow aggregates Journey Medical Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DERM to receive live email and push alerts on every new disclosure.